ReViral Appoints Brett Haumann as Chief Medical Officer
ReViral Ltd. today announced that Brett Haumann, MD, has joined the company as Chief Medical Officer. Dr. Haumann will be responsible for the company’s global clinical development and regulatory strategy as its lead candidate, sisunatovir, continues its progress through a phase 2 study in infants hospitalized with respiratory syncytial virus (RSV) respiratory tract infections.
“I am delighted to welcome Brett, a seasoned and highly respected clinician and leader, to ReViral,” said Alex C. Sapir, ReViral’s Chief Executive Officer. “Throughout his career, Brett has built a reputation as an outstanding leader among industry and medical communities in the US and Europe alike. Brett’s respiratory background and experience in combination drug development make him the ideal addition to the ReViral leadership team. I look forward to him applying that expertise to the further development of sisunatovir and our N-protein replication inhibitor program.”
Dr. Haumann joins ReViral after spending the past seven years as Chief Medical Officer and Senior Vice President of Development at Theravance Biopharma. During his tenure, he led a multi-functional organization developing a broad portfolio of novel assets in multiple therapeutic areas including respiratory and infectious diseases. He spent time in both European and US subsidiaries of the company and oversaw the successful development and first-cycle FDA approval of revefenacin (YUPELRI®) for the treatment of COPD. Before Theravance, Dr. Haumann spent more than 15 years in senior development roles at GlaxoSmithKline (GSK), including as Vice President of Clinical
Development, where he served as the global Medicines Development Leader, leading the successful development and approval of RELVAR®/BREO® for the treatment of asthma and COPD. Dr. Haumann has also served as a non-executive director on a number of private and public boards in Europe and the US, including most recently as the Head of the R&D Committee on the Board of Aimmune
Therapeutics, prior to its acquisition by Nestlé in 2020. Dr. Haumann holds an M.D. from Witwatersrand University in South Africa and an MBA from The Open University in the UK.
Dr. Haumann said: “I’m honored to have the opportunity to lead ReViral’s clinical development program at such an important moment in its evolution. I am looking forward to working with the company’s talented team to build a robust pipeline that has the potential to transform the care of RSV patients around the world.”
Other News
embecta and PolyPhotonix sign Partnership Agreement for Noctura 400 Sleep Mask
Kromek secures orders totalling over $1m in medical imaging
Clinical Services Advisor
Durham welcomes Annual North East Space Conference
Filtronic wins £2m satellite communications contract
Kromek Awarded Funding for £2.5m Breast Cancer Screening Solution Developments
Follow NETPark On Social Media
Keep up to date with the latest NETPark news and events.
The North East Technology Park provides a dynamic and supportive environment to accelerate the growth of ambitious, innovative, high tech companies into global markets. NETPark encourages collaborative multidisciplinary links, driving innovation, enterprise and economic prosperity.
We provide companies with access to a focused and international community where talent flourishes, ideas are generated and businesses have the support and resources to compete with the best in the world.
NETPark North East Technology Park
NETPark, North East Technology Park,
Sedgefield, County Durham TS21 3FD
Call Us: (+44) 01740 625250
Email: enquiries@northeasttechnologypark.com
Web: northeasttechnologypark.com
It fits perfectly for us that we’re surrounded by like-minded companies at NETPark. There are a number of highly skilled people in the area who can help us grow our business. The facilities and services offered by NETPark are first class, they make office life simple and engaging.
We initially came because of the printable electronics centre but access to a highly skilled semi conductor workforce in the North East has been a key factor in us staying and growing here, as well as the value for money office space and the access to funding.
The proximity to the universities and the infrastructure are very important factors. Ultimately having a presence in Europe is very valuable to us and we intend to stay at NETPark for many years to come.
The quality of the facilities at NETPark and the attitude of staff is first class. It has a really dynamic, innovative atmosphere.
CPI has developed a specialist offering to support SMEs looking to develop their printable electronics applications and our partnership with Business Durham has been instrumental in attracting several SMEs to locate here in the region.
Access to quality facilities was one of the main drivers for deciding to locate the business at the NETPark. We have been able to use this as a launch pad to link into support from CPI and world-class expertise from Durham University.